Multinational pharmaceutical comany Pfizer recently opened a phase 2 study of an experimental compound that may be beneficial in Duchenne muscular dystrophy (DMD) through its ability to block myostatin, a naturally occurring protein that is known to limit muscle growth.
SMT C1100, an experimental compound designed to boost levels of the potentially therapeutic protein utrophin in patients with Duchenne muscular dystrophy (DMD), will undergo further testing in boys with this disorder along with dietary specifications that may improve its absorption by the body, its developer has announced.
A phase 1-2 trial of ISIS-DMPKRx, an experimental compound for the treatment of type 1 myotonic muscular dystrophy, is now underway in the U.S. in adults with this disorder who are 20 to 55 years old and meet other study criteria.
Weeklong Campaign to Sell Custom-Designed T-shirts
Inspired by the Strength of MDA Families and Supporters
CHICAGO, Nov. 24, 2014 — The Muscular Dystrophy Association and Sevenly.org, known for its seven-day, limited edition charity T-shirt campaigns, announced today they will join forces in the fight against muscle disease with the sale of five custom-designed T-shirts to benefit individuals and families served by MDA.